Steph Habif, United States of America
Tandem Diabetes Care Behavioral SciencesPresenter of 1 Presentation
QUALITY OF LIFE OUTCOMES AND GLYCEMIC CONTROL FROM THE T:SLIM X2 PUMP WITH CONTROL-IQ TECHNOLOGY – REAL WORLD OBSERVATIONS FROM THE CLIO STUDY
Abstract
Background and Aims
To forward a holistic understanding of automated insulin dosing system efficacy, evaluation of both glycemic and psychosocial outcomes is necessary.
Methods
As part of the ongoing Control-IQ Observational (CLIO) Study, we evaluated glycemic and psychosocial outcomes in people with type 1 diabetes (PWT1D) using the Tandem Diabetes Care® t:slim X2™ insulin pump with Control-IQ® technology. Participants completed questionnaires at baseline (T1) and 3 months after study start (T2), uploaded at least 21 days of pump data to Tandem’s t:connect® web application, and had ≥75% CGM use during this time. Repeated measures ANOVA was used to assess differences in patient-reported outcomes from T1 to T2.
Results
In all, 700 PWT1D (59% female, 87% White, mean age=39 (SD=17), mean diabetes duration=21 years (SD=15)) were included in the analysis. 81% reported baseline HbA1c <8.5%, 80% had been using an insulin pump, and 89% were using CGM prior to using Control-IQ technology. At T2, sensor time in range for the overall sample using Control-IQ technology was 72.5% (median, IQR=71-73%) and sensor time <70mg/dl=1.1%. Participants reported greater satisfaction with their insulin delivery device and its impact on their diabetes management (7.06 vs. 8.77) (p<0.001). Majority (96%) reported improved sleep quality at T2. A significant reduction in the perceived negative impact of diabetes (4.79 vs 4.41) (p<0.001) (i.e., improved quality of life) across life dimensions (e.g., freedom to eat, emotional well-being) was noted.
Conclusions
Control-IQ technology users reported substantial psychosocial benefits including improved QoL, satisfaction, and sleep quality within three months of using the system.